These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7906292)

  • 1. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine.
    Katzenstein DA; Winters M; Bubp J; Israelski D; Winger E; Merigan TC
    J Infect Dis; 1994 Feb; 169(2):416-9. PubMed ID: 7906292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.
    Yerly S; Kaiser L; Baumberger C; Hirschel B; Perrin LH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):358-64. PubMed ID: 7882100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of antiretroviral therapy by plasma viral load testing: standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.
    Kappes JC; Saag MS; Shaw GM; Hahn BH; Chopra P; Chen S; Emini EA; McFarland R; Yang LC; Piatak M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):139-49. PubMed ID: 7552477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.
    Kojima E; Shirasaka T; Anderson BD; Chokekijchai S; Steinberg SM; Broder S; Yarchoan R; Mitsuya H
    J Infect Dis; 1995 May; 171(5):1152-8. PubMed ID: 7751690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
    Kahn JO; Lagakos SW; Richman DD; Cross A; Pettinelli C; Liou SH; Brown M; Volberding PA; Crumpacker CS; Beall G
    N Engl J Med; 1992 Aug; 327(9):581-7. PubMed ID: 1353607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.
    Holodniy M; Katzenstein D; Winters M; Montoya J; Shafer R; Kozal M; Ragni M; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1993 Apr; 6(4):366-9. PubMed ID: 8095981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction.
    Piatak M; Saag MS; Yang LC; Clark SJ; Kappes JC; Luk KC; Hahn BH; Shaw GM; Lifson JD
    AIDS; 1993 Nov; 7 Suppl 2():S65-71. PubMed ID: 7909227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in VACUTAINER CPT and standard VACUTAINER tubes.
    Mole L; Margolis D; Carroll R; Todd J; Holodniy M
    J Clin Microbiol; 1994 Sep; 32(9):2212-5. PubMed ID: 7814549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction.
    Edlin BR; Weinstein RA; Whaling SM; Ou CY; Connolly PJ; Moore JL; Bitran JD
    J Infect Dis; 1992 May; 165(5):793-8. PubMed ID: 1349031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy.
    Hamed KA; Winters MA; Holodniy M; Katzenstein DA; Merigan TC
    J Infect Dis; 1993 Apr; 167(4):798-802. PubMed ID: 8450243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.
    Holodniy M; Katzenstein DA; Israelski DM; Merigan TC
    J Clin Invest; 1991 Nov; 88(5):1755-9. PubMed ID: 1682345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue.
    Cohen OJ; Pantaleo G; Holodniy M; Schnittman S; Niu M; Graziosi C; Pavlakis GN; Lalezari J; Bartlett JA; Steigbigel RT
    Proc Natl Acad Sci U S A; 1995 Jun; 92(13):6017-21. PubMed ID: 7597072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
    Mueller BU; Sei S; Anderson B; Luzuriaga K; Farley M; Venzon DJ; Tudor-Williams G; Schwartzentruber DJ; Fox C; Sullivan JL; Pizzo PA
    J Pediatr; 1996 Sep; 129(3):410-8. PubMed ID: 8804331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S; Loveday C; Picazo JJ; Dellarnonica P; Skinhøj P; Johnson MA; Danner SA; Harrigan PR; Hill AM; Verity L; McDade H
    JAMA; 1996 Jul; 276(2):111-7. PubMed ID: 8656502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype.
    Holodniy M; Katzenstein D; Mole L; Winters M; Merigan T
    J Infect Dis; 1996 Oct; 174(4):854-7. PubMed ID: 8843229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures.
    Winters MA; Holodniy M; Katzenstein DA; Merigan TC
    PCR Methods Appl; 1992 May; 1(4):257-62. PubMed ID: 1477661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitation of unintegrated HIV-1 DNA in asymptomatic patients in the presence or absence of antiretroviral therapy.
    Bush CE; Donovan RM; Smereck SM; Strang D; Markowitz N; Saravolatz LD
    AIDS Res Hum Retroviruses; 1993 Feb; 9(2):183-7. PubMed ID: 8096146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus.
    Nelson MR; Moyle GJ; Gazzard BG
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S59-62. PubMed ID: 8093848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy.
    Perrin L; Yerly S; Marchal F; Schockmel GA; Hirschel B; Fox CH; Pantaleo G
    J Infect Dis; 1998 Jun; 177(6):1497-501. PubMed ID: 9607825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.